Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report)'s stock had its "hold" rating reissued by equities researchers at Brookline Capital Management in a report issued on Wednesday, Benzinga reports.
Other research analysts also recently issued research reports about the stock. Needham & Company LLC dropped their target price on shares of Verrica Pharmaceuticals from $16.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, August 15th. Royal Bank of Canada lowered their price objective on Verrica Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating on the stock in a research report on Thursday, August 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Verrica Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $12.25.
Check Out Our Latest Research Report on VRCA
Verrica Pharmaceuticals Stock Performance
Shares of NASDAQ VRCA traded down $0.26 during trading on Wednesday, hitting $1.11. The company had a trading volume of 1,497,657 shares, compared to its average volume of 372,357. Verrica Pharmaceuticals has a 12 month low of $1.04 and a 12 month high of $11.41. The company has a debt-to-equity ratio of 29.58, a quick ratio of 2.23 and a current ratio of 2.36. The firm has a market capitalization of $47.09 million, a P/E ratio of -0.64 and a beta of 1.48. The stock has a 50 day simple moving average of $3.34 and a 200 day simple moving average of $6.00.
Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. The business had revenue of $5.18 million for the quarter, compared to the consensus estimate of $4.70 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. As a group, analysts anticipate that Verrica Pharmaceuticals will post -1.56 earnings per share for the current year.
Insider Activity at Verrica Pharmaceuticals
In other Verrica Pharmaceuticals news, insider Joe Bonaccorso sold 25,461 shares of the business's stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $7.06, for a total value of $179,754.66. Following the sale, the insider now owns 106,931 shares in the company, valued at approximately $754,932.86. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Ted White sold 32,469 shares of the stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $7.06, for a total transaction of $229,231.14. Following the completion of the transaction, the chief executive officer now directly owns 250,121 shares in the company, valued at approximately $1,765,854.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Joe Bonaccorso sold 25,461 shares of the firm's stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $7.06, for a total transaction of $179,754.66. Following the completion of the transaction, the insider now directly owns 106,931 shares of the company's stock, valued at $754,932.86. The disclosure for this sale can be found here. 42.60% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Verrica Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. Simplify Asset Management Inc. bought a new stake in shares of Verrica Pharmaceuticals in the 2nd quarter worth about $2,041,000. Renaissance Technologies LLC purchased a new position in Verrica Pharmaceuticals in the second quarter worth about $332,000. Quest Partners LLC bought a new stake in Verrica Pharmaceuticals during the second quarter worth approximately $50,000. Rhumbline Advisers raised its position in Verrica Pharmaceuticals by 20.4% during the second quarter. Rhumbline Advisers now owns 26,591 shares of the company's stock valued at $194,000 after purchasing an additional 4,514 shares during the period. Finally, Key Financial Inc purchased a new stake in Verrica Pharmaceuticals during the second quarter valued at approximately $69,000. Hedge funds and other institutional investors own 42.45% of the company's stock.
About Verrica Pharmaceuticals
(
Get Free Report)
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
See Also
Before you consider Verrica Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.
While Verrica Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
